<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Genotypic testing of nonselected patients with the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) for the C282Y and H63D mutations of the HFE gene responsible for hereditary <z:mp ids='MP_0005638'>hemochromatosis</z:mp> revealed a significantly increased frequency of these mutations when compared to healthy blood donors reflecting the average population </plain></SENT>
<SENT sid="1" pm="."><plain>Among the 50 patients examined [26 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), 9 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), 2 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) and 13 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t)] there were 24 heterozygotes (20 for H63D and 4 for C282Y), 1 homozygote for H63D and 1 compound heterozygote </plain></SENT>
<SENT sid="2" pm="."><plain>The difference between the HFE-positive and HFE-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients as regards initial serum iron and transferrin saturation was not significant </plain></SENT>
<SENT sid="3" pm="."><plain>Inevitably the <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> syndrome eventually develops in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients due to intrinsic characteristics of the disease as well as an escalating need for blood transfusion therapy in the course of the disease </plain></SENT>
<SENT sid="4" pm="."><plain>The high incidence rate of HFE gene mutations among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients may also contribute to this vicious circle </plain></SENT>
</text></document>